GlassScriptPhysician profile
Benedict O Okwara
NPI 1487613840
$5,601.90
in general payments reported to CMS, 2019-2025
45 companies · $822 in 2025
The $822 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $539 · 2021: $665 · 2022: $708 · 2023: $1,086 · 2024: $925 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,616.63 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $675.94 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $439.04 | 2021-2025 | |
| Pfizer INC. | $426.58 | 2019-2025 | |
| Gilead Sciences, INC. | $209.48 | 2019-2022 | |
| Horizon Therapeutics Plc | $176.17 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $169.51 | 2019-2023 | |
| Lilly USA, LLC | $143.91 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Vertex Pharmaceuticals Incorporated | $140.12 | 2024 | |
| Novo Nordisk INC | $137.39 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $130.72 | 2023-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.41 | 2022-2025 | Jardiance, Synjardy |
| Viiv Healthcare Company | $125.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $107.00 | 2019 | |
| Exact Sciences Corporation | $100.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benedict Okwara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.